RANITAL 50 mg/5 mL rastvor  za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

ranital 50 mg/5 ml rastvor za injekciju

novartis ba d.o.o. - ranitidin - rastvor za injekciju - 50 mg/5 ml - 1 ampula sa 5 ml rastvora za injekciju sadrži: 56 mg ranitidin hidrohlorida (što odgovara 50 mg ranitidina)

Phemiton 200 mg tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

phemiton 200 mg tablete

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - metilfenobarbital - tableta - 200 mg - urbroj: svaka tableta sadrži 200 mg metilfenobarbitala

Gastrobel 150 mg šumeće tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

gastrobel 150 mg šumeće tablete

belupo lijekovi i kozmetika d.d., ulica danica 5, koprivnica - ranitidinum - šumeća tableta - 150 mg - urbroj: jedna šumeća tableta sadrži 150 mg ranitidina u obliku ranitidinklorida

Tagrisso Europska Unija - hrvatski - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - karcinom, ne-malih stanica pluća - drugi antitumorski lijekovi, inhibitori протеинкиназы - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Martefarin 3 mg tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

martefarin 3 mg tablete

orion corporation, orionintie 1, espoo, finska - varfarinnatrij - tableta - 3 mg - urbroj: jedna tableta sadrži 3 mg varfarinnatrija